KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer

KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer
Conditions: Gastric Cancer; Esophagus Cancer

Interventions: Drug: Oxaliplatin+Capecitabine+Pembrolizumab

Sponsors: Duke University; Merck Sharp & Dohme LLC

Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 14, 2024Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments